Şirket yükleniyor
Just reported
Q2 FY2027 results
From Canopy Growth's results release of 6 Kasım 2026; its quarterly report has since been filed.
Revenue
Actual
$81,4M
+%22 y/y
+%0,3 q/qGuided
—
No guide given
EPS, GAAP
Actual
-$0,10
Guided
—
No guide given
Operating income, GAAP
Actual
-$23M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Canopy Growth is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$34,4BA
NBIXNeurocrine Biosciences, Inc.$16,9BA+
ELANElanco Animal Health Incorporated$13,4BA
KNSAKiniksa Pharmaceuticals International, plc$8,2BA+
LQDALiquidia Corporation$5,2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 Eki 2026CAGraded C, now A
Canopy Growth Corporation şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu şirket CAD cinsinden raporluyor. Rakamlar güncel kur olan $1,00 = 1,4258 CAD üzerinden, tüm dönemlere aynı şekilde uygulanarak dolara çevrildi — böylece büyüme ve marjlar şirkete ait olur, kura değil. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
